Updated:
Novotech (Australia) Pty Limited
Novotech runs clinical trials across the Asia-Pacific region, giving biotech sponsors a regulatory and operational gateway into Australia and key Asian...
Novotech (Australia) Pty Limited
Novotech (Australia) Pty Limited operates as a full-service contract research organization (CRO) specializing in Asia-Pacific clinical development, with its principal operational base in Sydney. The firm was founded in 1996 and subsequently expanded through the Australasian region before building a broader pan-Asian presence. The entity functions as the core operating company for the Novotech group, which also includes offices in Singapore, India, South Korea, Malaysia, and Hong Kong. Unlike investment firms, Novotech generates revenue by executing drug-development services for biopharmaceutical sponsors, primarily small to mid-cap biotechs from North America and Europe seeking faster, cost-effective clinical pathways in APAC. The firm's service deployment spans Phase I through Phase IV clinical trials, with particular strength in early-phase oncology studies. Its therapeutic coverage runs deep across more than a dozen areas, including oncology, infectious diseases, central nervous system disorders, and rare diseases. Operational capabilities extend beyond traditional trial management to encompass regulatory consulting, medical writing, data management, biostatistics, and pharmacovigilance. Novotech's value proposition hinges on its proprietary investigator-site network and patient-reach data, which allow sponsors to accelerate site selection and patient recruitment — the two highest-friction variables in clinical trial execution. The firm has supported more than 5,000 clinical projects since inception, a scale that places it among the largest Asia-focused CROs by project volume. Novotech competes with global CROs such as IQVIA and Parexel for regional work but differentiates through its deep local regulatory knowledge and a single-region focus. The management team, historically led by figures such as CEO Dr. John Moller, has maintained close operational ties to Australia's Therapeutic Goods Administration (TGA) and to Asia-Pacific ethics committees. In recent years, the firm welcomed a strategic investment from TPG Capital, although Novotech continues to operate as an independent clinical services company under that agreement. The Sydney headquarters anchors a distributed workforce of more than 3,000 professionals across the region. A genuine structural differentiator is Novotech's proprietary data asset: 20-plus years of historical clinical-performance metrics across APAC sites that rival CROs cannot replicate, because they have not concentrated their operations in the region to the same degree. This data enables benchmarking that materially de-risks site selection for sponsors unfamiliar with Asian regulatory environments. The asset is reinforced by Novotech's broad TGA and Ethics Committee submissions, which create a repeatable, high-velocity approval pathway for biotech clients that larger, diversified CROs struggle to match within single-region cost structures.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Australia
City
Sydney
Corporate office
Sydney, Australia
Sector focus
Frequently asked questions
Who owns Novotech and how is it capitalized?
TPG Capital acquired a majority stake in Novotech in 2017, and the firm has operated under TPG's ownership since that transaction. The CRO generates revenue through fee-for-service clinical-trial contracts rather than through capital deployment, so traditional AUM or fund metrics do not apply. The TPG backing supplies the balance-sheet strength needed to maintain a 3,000-plus professional workforce and to invest in the proprietary site-and-patient data infrastructure that underpins its competitive moat.
How does Novotech source new sponsor relationships?
Novotech sources the majority of its new sponsor relationships through its business development teams stationed in North America, Europe, and Asia. The firm runs a proactive outreach model aimed at small- to mid-cap biotech companies that are planning first-in-human or early-phase studies and need an APAC regulatory pathway. Its repeat-business rate is reinforced by a 20-plus-year operational track record that includes more than 5,000 completed clinical projects, which functions as a reference base when competing against larger global CROs.
What therapeutic areas does Novotech specialize in?
Novotech's oncology practice represents its deepest domain, having managed hundreds of cancer trials across Asia-Pacific. Beyond oncology, the CRO maintains dedicated therapeutic teams in infectious diseases, central nervous system disorders, cardiovascular and metabolic diseases, and rare diseases. The firm's clinical operations teams are organized around these therapy areas to ensure protocol-specific expertise at both the project-management and site-monitoring levels.
Is Novotech structured as an investment firm or a service provider?
Novotech is a contract research organization, not an investment firm or family office. It employs more than 3,000 clinical research professionals and generates revenue by delivering drug-development services to biopharmaceutical sponsors. The company does not invest equity in the programs it runs, does not hold an investment portfolio, and does not report AUM or deployment figures.
Which regions does Novotech's operational footprint actually cover?
The firm's physical footprint spans Australia, New Zealand, Singapore, South Korea, Malaysia, India, Hong Kong, and mainland China. Its Australian base, anchored in Sydney, serves as the gateway for North American and European sponsors seeking rapid TGA-governed early-phase studies. The broader Asia network allows sponsors to run multi-country trials under a single CRO contract, which simplifies vendor management relative to stitching together country-specific providers.
What is Novotech's known posture on working alongside other CROs?
Novotech positions itself as a full-service APAC partner, which means the firm is typically awarded sole-CRO contracts for regional trial execution rather than serving as a functional-service provider alongside other CROs. In practice, a sponsor running a global pivotal trial might contract a large Western CRO for North American and European sites while awarding the Asia-Pacific portion exclusively to Novotech, a structure that the firm actively encourages.
Does Novotech maintain distinct philanthropic or investment arms?
Novotech is not known to operate any philanthropic foundations, venture-capital vehicles, or real-asset investment arms. The business model is confined to clinical research services. Any corporate social-responsibility activities appear to be managed within the operating company rather than through separately structured entities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: